Not checkedNot checked for notices yet.
Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
Hisham Abdelmotilib, Andrew B. West
Genome Medicine · 2017
doi:10.1186/s13073-017-0483-4 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.